新型生物标志物在睾丸癌化疗后残余肿块管理中的应用概述。

Overview of Novel Biomarkers for Management of Postchemotherapy Residual Masses in Testicular Cancer.

机构信息

State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China; Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China.

State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China; Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China.

出版信息

Eur Urol Focus. 2024 May;10(3):380-382. doi: 10.1016/j.euf.2024.05.001. Epub 2024 May 9.

DOI:10.1016/j.euf.2024.05.001

Abstract

The diagnosis of postchemotherapy residual masses in testicular cancer must be based on the integration of clinical, imaging, and serology tests. Further validation is needed for novel biomarkers.

摘要

精原细胞瘤化疗后残余灶的诊断必须基于临床、影像学和血清学检查的综合判断。需要进一步验证新型生物标志物。

相似文献

1

Overview of Novel Biomarkers for Management of Postchemotherapy Residual Masses in Testicular Cancer.

Eur Urol Focus. 2024 May;10(3):380-382. doi: 10.1016/j.euf.2024.05.001. Epub 2024 May 9.

2

Management of residual disease after chemotherapy in germ cell tumors.

Curr Opin Oncol. 2020 May;32(3):250-255. doi: 10.1097/CCO.0000000000000619.

3

External validation of 2 models to predict necrosis/fibrosis in postchemotherapy residual retroperitoneal masses of patients with advanced testicular cancer.

Urol Oncol. 2019 Nov;37(11):809.e9-809.e18. doi: 10.1016/j.urolonc.2019.07.021. Epub 2019 Sep 17.

4

Outcomes in Patients With Postchemotherapy Residual Nonretroperitoneal Disease in Nonseminomatous Germ Cell Tumors.

JAMA Oncol. 2024 Jan 1;10(1):132-134. doi: 10.1001/jamaoncol.2023.4949.

5

Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses?

J Clin Oncol. 1992 Apr;10(4):569-73. doi: 10.1200/JCO.1992.10.4.569.

6

Postchemotherapy Resection of Residual Mass in Nonseminomatous Germ Cell Tumor.

Urol Clin North Am. 2019 Aug;46(3):389-398. doi: 10.1016/j.ucl.2019.04.004. Epub 2019 May 21.

7

Tumors of the Testis: Morphologic Features and Molecular Alterations.

Surg Pathol Clin. 2015 Dec;8(4):687-716. doi: 10.1016/j.path.2015.07.007.

8

Outcomes after resection of postchemotherapy residual neck mass in patients with germ cell tumors--an update.

Urology. 2011 Mar;77(3):655-9. doi: 10.1016/j.urology.2010.10.002.

9

Postchemotherapy changes in testicular germ cell tumours: biology and morphology.

Histopathology. 2017 Jan;70(1):26-39. doi: 10.1111/his.13078.

10

Postchemotherapy residual masses in germ cell tumor patients: our experience.

Ann Oncol. 2006 Jun;17 Suppl 7:vii132-6. doi: 10.1093/annonc/mdl966.

引用本文的文献

1

A predictive system comprising serum microRNAs and radiomics for residual retroperitoneal masses in metastatic nonseminomatous germ cell tumors.

Cell Rep Med. 2024 Dec 17;5(12):101843. doi: 10.1016/j.xcrm.2024.101843. Epub 2024 Dec 12.

2

Nuclear medicine imaging in non-seminomatous germ cell tumors: lessons learned from the past failures.

Cancer Imaging. 2024 Nov 18;24(1):156. doi: 10.1186/s40644-024-00794-5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。